| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Real-Time Polymerase Chain Reaction | 5 | 2014 | 301 | 0.950 |
Why?
|
| beta-Lactamases | 3 | 2013 | 58 | 0.790 |
Why?
|
| Polymerase Chain Reaction | 10 | 2020 | 894 | 0.770 |
Why?
|
| DNA Primers | 5 | 2011 | 530 | 0.440 |
Why?
|
| Placenta | 3 | 2025 | 202 | 0.440 |
Why?
|
| Bacteriological Techniques | 2 | 2012 | 39 | 0.430 |
Why?
|
| Klebsiella Infections | 2 | 2012 | 35 | 0.420 |
Why?
|
| Klebsiella pneumoniae | 2 | 2012 | 37 | 0.420 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2025 | 100 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 769 | 0.390 |
Why?
|
| Anal Canal | 1 | 2013 | 94 | 0.370 |
Why?
|
| Neonatal Sepsis | 2 | 2023 | 5 | 0.370 |
Why?
|
| Transforming Growth Factor beta | 4 | 2024 | 356 | 0.350 |
Why?
|
| Adenoviridae | 3 | 2024 | 340 | 0.330 |
Why?
|
| Mutation | 7 | 2024 | 4396 | 0.330 |
Why?
|
| Bacteria | 2 | 2023 | 545 | 0.320 |
Why?
|
| DNA, Bacterial | 4 | 2020 | 236 | 0.310 |
Why?
|
| Oncolytic Virotherapy | 2 | 2020 | 36 | 0.300 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 48 | 0.300 |
Why?
|
| BRCA2 Protein | 1 | 2009 | 177 | 0.280 |
Why?
|
| BRCA1 Protein | 1 | 2009 | 222 | 0.270 |
Why?
|
| RNA, Viral | 3 | 2025 | 287 | 0.270 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2007 | 18 | 0.250 |
Why?
|
| Plasmodium | 1 | 2005 | 11 | 0.220 |
Why?
|
| Placenta Diseases | 1 | 2025 | 18 | 0.220 |
Why?
|
| Malaria | 1 | 2005 | 28 | 0.220 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2010 | 116 | 0.220 |
Why?
|
| Abortion, Spontaneous | 1 | 2025 | 74 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2024 | 116 | 0.210 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1211 | 0.210 |
Why?
|
| Fetus | 1 | 2025 | 238 | 0.210 |
Why?
|
| Adenoviridae Infections | 1 | 2024 | 16 | 0.200 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2024 | 59 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 82 | 0.190 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 316 | 0.180 |
Why?
|
| Genes, ras | 5 | 1995 | 97 | 0.180 |
Why?
|
| Sepsis | 2 | 2023 | 401 | 0.170 |
Why?
|
| Genetic Vectors | 2 | 2020 | 426 | 0.170 |
Why?
|
| ROC Curve | 2 | 2021 | 793 | 0.160 |
Why?
|
| Fetal Blood | 1 | 2021 | 94 | 0.160 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 212 | 0.160 |
Why?
|
| Humans | 33 | 2025 | 97894 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2020 | 10 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 569 | 0.160 |
Why?
|
| Oncolytic Viruses | 1 | 2019 | 20 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2018 | 142 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2020 | 126 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 160 | 0.130 |
Why?
|
| Liver | 3 | 2025 | 1231 | 0.130 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 285 | 0.130 |
Why?
|
| Pancreatic Ducts | 2 | 1994 | 37 | 0.130 |
Why?
|
| Influenza, Human | 2 | 2010 | 357 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 604 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1944 | 0.110 |
Why?
|
| Point Mutation | 2 | 2013 | 237 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1764 | 0.110 |
Why?
|
| Prevalence | 2 | 2023 | 1384 | 0.110 |
Why?
|
| Base Sequence | 6 | 2007 | 2222 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 269 | 0.110 |
Why?
|
| Autopsy | 2 | 2025 | 131 | 0.100 |
Why?
|
| Paraffin Embedding | 2 | 2013 | 77 | 0.100 |
Why?
|
| Formaldehyde | 2 | 2013 | 52 | 0.100 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 43 | 0.100 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2013 | 5 | 0.100 |
Why?
|
| Clarithromycin | 1 | 2013 | 7 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2014 | 201 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 85 | 0.100 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 1836 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 41 | 0.100 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 36 | 0.090 |
Why?
|
| Pregnancy | 3 | 2025 | 3246 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 36 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2013 | 66 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1995 | 461 | 0.090 |
Why?
|
| Gastritis | 1 | 2013 | 38 | 0.090 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 108 | 0.090 |
Why?
|
| Nucleic Acids | 1 | 2013 | 36 | 0.090 |
Why?
|
| Oncogenes | 2 | 1995 | 102 | 0.090 |
Why?
|
| Thyroidectomy | 1 | 2013 | 181 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 89 | 0.090 |
Why?
|
| Stomach | 1 | 2013 | 110 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2006 | 500 | 0.090 |
Why?
|
| Adult | 10 | 2025 | 29453 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 548 | 0.090 |
Why?
|
| Culture Media | 1 | 2012 | 138 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 157 | 0.090 |
Why?
|
| Adenoma, Islet Cell | 1 | 1992 | 28 | 0.090 |
Why?
|
| Female | 13 | 2025 | 51464 | 0.090 |
Why?
|
| Rodentia | 1 | 1992 | 49 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 826 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 290 | 0.080 |
Why?
|
| Virology | 1 | 2010 | 13 | 0.080 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 13 | 0.080 |
Why?
|
| Robotics | 1 | 2013 | 271 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 74 | 0.080 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2010 | 90 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 177 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2013 | 490 | 0.070 |
Why?
|
| Neoplasms | 2 | 2022 | 3340 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 2892 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 1103 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7386 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2023 | 10947 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2529 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2009 | 162 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2009 | 191 | 0.070 |
Why?
|
| Animals | 11 | 2024 | 28910 | 0.070 |
Why?
|
| Species Specificity | 2 | 2007 | 690 | 0.070 |
Why?
|
| Middle Aged | 9 | 2024 | 29353 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 557 | 0.070 |
Why?
|
| Cytokines | 2 | 2024 | 889 | 0.070 |
Why?
|
| DNA | 2 | 2009 | 1274 | 0.060 |
Why?
|
| Chlamydophila psittaci | 1 | 2007 | 2 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 872 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2007 | 25 | 0.060 |
Why?
|
| Chlamydia Infections | 1 | 2007 | 30 | 0.060 |
Why?
|
| Male | 12 | 2024 | 46996 | 0.060 |
Why?
|
| Aged | 7 | 2024 | 21702 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2013 | 791 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 51 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 831 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 900 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1750 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3272 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 2896 | 0.060 |
Why?
|
| Pregnancy Trimesters | 1 | 2025 | 6 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 24 | 0.060 |
Why?
|
| DNA, Protozoan | 1 | 2005 | 15 | 0.060 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2005 | 26 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 28 | 0.060 |
Why?
|
| Cell Line | 1 | 2009 | 2483 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 1778 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 262 | 0.050 |
Why?
|
| Genes, p53 | 2 | 1995 | 108 | 0.050 |
Why?
|
| Cell Communication | 1 | 2005 | 223 | 0.050 |
Why?
|
| Mice | 5 | 2024 | 12707 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 902 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2005 | 327 | 0.050 |
Why?
|
| Mesocricetus | 5 | 1995 | 103 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1995 | 166 | 0.050 |
Why?
|
| Cricetinae | 5 | 1995 | 533 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 185 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2024 | 3623 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 889 | 0.050 |
Why?
|
| Young Adult | 3 | 2025 | 7504 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 50 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2021 | 39 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 462 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 267 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1995 | 0.040 |
Why?
|
| Hospitals | 2 | 2013 | 335 | 0.040 |
Why?
|
| Carcinogens | 3 | 1995 | 102 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 64 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2007 | 157 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 161 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 146 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2783 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 155 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2572 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1028 | 0.040 |
Why?
|
| Gene Expression | 2 | 1994 | 1320 | 0.040 |
Why?
|
| Lung | 1 | 2025 | 1406 | 0.030 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 830 | 0.030 |
Why?
|
| Methylnitrosourea | 2 | 1994 | 7 | 0.030 |
Why?
|
| Virus Replication | 1 | 2019 | 292 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 200 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 106 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 291 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 913 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1121 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 237 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 400 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4112 | 0.030 |
Why?
|
| Cell Aggregation | 2 | 2006 | 37 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1992 | 1394 | 0.030 |
Why?
|
| Culture Media, Conditioned | 2 | 2006 | 102 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 21 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Nitrosourea Compounds | 1 | 1994 | 9 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 911 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 49 | 0.030 |
Why?
|
| Child | 2 | 2020 | 7680 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 5555 | 0.030 |
Why?
|
| Exons | 2 | 1995 | 451 | 0.020 |
Why?
|
| Fixatives | 1 | 2013 | 13 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2013 | 47 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2013 | 39 | 0.020 |
Why?
|
| Kallikreins | 1 | 2013 | 47 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 87 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 10078 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 889 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2013 | 74 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 150 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 2012 | 5 | 0.020 |
Why?
|
| Agar | 1 | 2012 | 9 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 4000 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2013 | 113 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1009 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 920 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1193 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1565 | 0.020 |
Why?
|
| Illinois | 1 | 2013 | 522 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 1992 | 191 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 150 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1527 | 0.020 |
Why?
|
| Trout | 1 | 1991 | 2 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1992 | 218 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 354 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1995 | 750 | 0.020 |
Why?
|
| General Surgery | 1 | 2013 | 262 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1094 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2009 | 51 | 0.020 |
Why?
|
| Introns | 1 | 1991 | 301 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 133 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 260 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1994 | 2855 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 1224 | 0.020 |
Why?
|
| Nitrosamines | 3 | 1995 | 9 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1815 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 3202 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 1513 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2063 | 0.020 |
Why?
|
| Mass Screening | 1 | 2012 | 745 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 2005 | 12 | 0.010 |
Why?
|
| Transition Temperature | 1 | 2005 | 9 | 0.010 |
Why?
|
| DNA Probes | 1 | 2005 | 66 | 0.010 |
Why?
|
| Blood | 1 | 2005 | 68 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 175 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 102 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2005 | 269 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 689 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 313 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 3329 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 356 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 815 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1995 | 38 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 380 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 403 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 582 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1995 | 353 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 148 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1995 | 682 | 0.010 |
Why?
|